ALB and type 2 diabetes mellitus: When MARS was first introduced to treat patients with hepatic failure and coma, it was believed that its effective removal of protein-bound toxins of liver failure was due to albumin, which somehow entered the membrane to directly contact plasma proteins and transfer toxins to the albumin.